 |
Journal articles
CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.
Françoise Solly
1, 2
Fanny Angelot
2, 3
Richard Garand
4
Christophe Ferrand
2, 3
Estelle Seillès
2, 3
Françoise Schillinger
2
Agnès Decobecq
2
Maryse Billot
2
Fabrice Larosa
5
Emmanuel Plouvier
6
Eric Deconinck
3, 5
Faezeh Legrand
5
Philippe Saas
2, 3
Pierre-Simon Rohrlich
3, 6
Francine Garnache-Ottou
2, 3, *
Françoise Solly 1, 2
Author
Fanny Angelot 2, 3
Author
Richard Garand 4
Author
Christophe Ferrand 2, 3
Author
Estelle Seillès 2, 3
Author
Françoise Schillinger 2
Author
Agnès Decobecq 2
Author
Maryse Billot 2
Author
Fabrice Larosa 5
Author
Emmanuel Plouvier 6
Author
Eric Deconinck 3, 5
Author
Faezeh Legrand 5
Author
Philippe Saas 2, 3
Author
Pierre-Simon Rohrlich 3, 6
Author
Francine Garnache-Ottou 2, 3
Correspondent author
2
Laboratoire d'hémostase, cytologie, plateforme de biomonitoring (1 bd Fleming 25020 Besançon - France)
- EFS [Bourgogne-Franche-Comté] - Etablissement français du sang [Bourgogne-Franche-Comté] (1 Boulevard Fleming 25020 Besançon cedex - France)
3
RIGHT - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (I.B.C.T.
Bâtiment Inserm
240 Route de Dole/Rue F. Dolto
25000 Besançon - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1098 (101, rue de Tolbiac, 75013 Paris - France)
- UFC - Université de Franche-Comté (1 rue Goudimel 25030 Besançon cedex - France)
- EFS [Bourgogne-Franche-Comté] - Etablissement français du sang [Bourgogne-Franche-Comté] (1 Boulevard Fleming 25020 Besançon cedex - France)
4
Laboratoire d'Hematologie (44094 Nantes - France)
- UN - Université de Nantes (1, quai de Tourville - BP 13522 - 44035 Nantes cedex 1 - France)
- CHU Nantes - Centre hospitalier universitaire de Nantes (1 Place Alexis-Ricordeau, 44000 Nantes - France)
5
Service d'hématologie (France)
Abstract : Minimal residual disease (MRD) has emerged as a major prognostic factor for monitoring patients with B-lineage acute lymphoblastic leukemia (B-ALL). The quantification of MRD by flow cytometry (FC) is based on the identification of a leukemia-associated phenotype (LAP). Because phenotypic switch is common during treatment, multiple LAPs must be available and used for MRD detection over time. We evaluated the potential usefulness of CD304 as a new marker for monitoring MRD. CD304 was expressed in 48% of B-ALL (24/50) with discriminative fluorescence intensity compared with CD304-negative normal B-cell precursors (n = 15). The sensitivity of CD304-based MRD detection reached 10(-4), as with some of established LAPs. The stability of CD304 expression evaluated during therapy and at relapse confirms the usefulness of this marker for MRD quantification. Finally, CD304 was repeatedly expressed in patients with TEL-AML1 gene rearrangement, which warrants further investigation on its potential relevance as a prognosis marker or therapeutic target.
Document type :
Journal articles
Domain :
Complete list of metadata
https://www.hal.inserm.fr/inserm-00799678
Contributor : Philippe Saas <>
Submitted on : Tuesday, March 12, 2013 - 3:07:00 PM
Last modification on : Thursday, January 21, 2021 - 2:10:03 PM
Contributor : Philippe Saas <>
Submitted on : Tuesday, March 12, 2013 - 3:07:00 PM
Last modification on : Thursday, January 21, 2021 - 2:10:03 PM
Links full text
Identifiers
- HAL Id : inserm-00799678, version 1
- DOI : 10.1002/cyto.a.21162
- PUBMED : 22052678
Collections
INSERM | UNIV-NANTES | UNIV-FCOMTE | UMR645
Citation
Françoise Solly, Fanny Angelot, Richard Garand, Christophe Ferrand, Estelle Seillès, et al.. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.. Cytometry Part A, Wiley, 2012, 81 (1), pp.17-24. ⟨10.1002/cyto.a.21162⟩. ⟨inserm-00799678⟩
Metrics
Record views